Today: 23 March 2026
Subscribe
Browse Category

Stock Market 10 January 2026

Marvell Technology stock slips after insider sale filing; AI deal digested as CPI looms

Marvell Technology stock slips after insider sale filing; AI deal digested as CPI looms

Marvell Technology shares fell 0.3% to $83.22 Friday, extending their weekly loss to about 8%. SEC filings showed Chief Legal Officer Mark Casper sold 5,000 shares at $93.08 each. The drop follows Marvell’s $540 million deal to acquire XConn Technologies. Investors are watching for next week’s U.S. CPI report and Marvell’s earnings in early March.
10 January 2026
··
Coherent stock snaps back after steep slide as jobs data lifts tech — what COHR traders watch next

Coherent stock snaps back after steep slide as jobs data lifts tech — what COHR traders watch next

Coherent shares rose 2.8% to $178.06 Friday, rebounding after a 9.6% drop the previous day. The move followed a softer U.S. jobs report that shifted rate expectations and lifted tech stocks. Coherent’s next earnings report is expected in early February, with investors watching U.S. CPI data on Jan. 13. The stock’s price-to-earnings ratio stands at 227.5, well above the industry median.
10 January 2026
··
Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Lululemon shares fell 3.9% Friday, closing at $203.90 after dipping near $200. The drop followed uncertainty over U.S. Supreme Court action on tariffs, with a ruling possible Jan. 14. CEO Calvin McDonald will step down Jan. 31, with two interim co-CEOs named. Founder Chip Wilson has launched a proxy fight, nominating three directors amid pressure from Elliott Management.
10 January 2026
·
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
NuScale Power stock jumps after Bank of America upgrade as Meta nuclear pacts lift SMR trade

NuScale Power stock jumps after Bank of America upgrade as Meta nuclear pacts lift SMR trade

NuScale Power shares rose 4.3% to $20.51 in after-hours trading Friday after Bank of America upgraded the stock to neutral with a $28 target, citing funding and timing challenges. Meta’s new nuclear power deals fueled sector-wide gains, with Vistra and Oklo jumping nearly 14%. Options trading in NuScale surged 31% above average. The stock remains below key moving averages ahead of earnings expected March 2.
10 January 2026
····
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.
10 January 2026
···
P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

Procter & Gamble will change Kid’s Crest toothpaste packaging after Texas officials said label artwork encouraged unsafe fluoride use by children. The rollout began Jan. 1 and must last five years. P&G shares closed up 0.24% at $141.87, then slipped 0.17% after hours. Investors await the Jan. 22 earnings call for updates on volumes, pricing, and regulatory scrutiny.
10 January 2026
··
Zillow stock stumbles after Mizuho downgrade flags listing-access fight and Flex legal risk

Zillow stock stumbles after Mizuho downgrade flags listing-access fight and Flex legal risk

Zillow shares fell about 2% Friday after Mizuho downgraded the stock to Neutral and slashed its price target to $70, citing legal risks over home listings and uncertainty around the Flex program. The downgrade comes as a court ruling nears in a Compass lawsuit challenging Zillow’s listing access policy. Rising mortgage rates and new federal bond purchases have added volatility to housing stocks. Analyst targets for Zillow have dropped in recent months.
10 January 2026
··
1 … 567 568 569 570 571 … 1,359

Stock Market Today

  • Gold Outperforms S&P 500 Over Five Years but Lloyds Banking Shows Strong Gains
    March 23, 2026, 4:13 AM EDT. Over the past five years, gold prices have surged 178.5%, delivering a compound annual growth rate (CAGR) of 22.7%, outperforming the S&P 500's 13.6% CAGR for UK investors after accounting for currency effects and dividends. The S&P 500's total return, including dividends, was 89.2%. Gold's appeal lies in its scarcity and multiple uses, though it yields no income. Meanwhile, UK banking stock Lloyds Banking Group delivered a 135.6% gain over five years, excluding dividends, with a current dividend yield of 3.8%, exceeding the FTSE 100 average. Lloyds shares recently declined amid geopolitical tensions and economic concerns, highlighting potential risks for investors in cyclical sectors despite historic gains.
Go toTop